Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.

Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Lephart PR, Chopra T, Hayakawa K, Martin ET, Abreu-Lanfranco O, Dhar S, Kaye KS, Marchaim D.

Am J Infect Control. 2012 Dec;40(10):983-7. doi: 10.1016/j.ajic.2011.12.014. Epub 2012 Mar 21.

PMID:
22440526
2.

Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.

Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC.

Crit Care Med. 2015 Jun;43(6):1194-204. doi: 10.1097/CCM.0000000000000933.

PMID:
25793437
3.

In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.

Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M.

J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.

PMID:
24265334
4.

Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.

Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA.

Infection. 2011 Dec;39(6):515-8. doi: 10.1007/s15010-011-0161-1. Epub 2011 Jul 26.

PMID:
21789524
5.

Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center.

Marchaim D, Chopra T, Perez F, Hayakawa K, Lephart PR, Bheemreddy S, Blunden C, Hujer AM, Rudin S, Shango M, Campbell M, Varkey J, Slim J, Ahmad F, Patel D, Chen TY, Pogue JM, Salimnia H, Dhar S, Bonomo RA, Kaye KS.

Infect Control Hosp Epidemiol. 2011 Sep;32(9):861-71. doi: 10.1086/661597.

6.

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249.

PMID:
18684704
7.

Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.

Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A.

Int J Antimicrob Agents. 2014 Apr;43(4):378-82. doi: 10.1016/j.ijantimicag.2014.01.016. Epub 2014 Feb 14.

PMID:
24613422
8.

In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.

Park GC, Choi JA, Jang SJ, Jeong SH, Kim CM, Choi IS, Kang SH, Park G, Moon DS.

Ann Lab Med. 2016 Mar;36(2):124-30. doi: 10.3343/alm.2016.36.2.124.

9.

In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.

J Antimicrob Chemother. 2007 Aug;60(2):317-22. Epub 2007 May 31.

PMID:
17540672
10.

Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.

Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD.

Scand J Infect Dis. 2013 Apr;45(4):315-9. doi: 10.3109/00365548.2012.732705. Epub 2012 Oct 31.

PMID:
23113680
11.

Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.

Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, Chong YP, Hong SB.

PLoS One. 2016 Mar 2;11(3):e0150642. doi: 10.1371/journal.pone.0150642. eCollection 2016.

12.

Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.

Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T.

Int J Antimicrob Agents. 2012 Oct;40(4):332-6. doi: 10.1016/j.ijantimicag.2012.06.003. Epub 2012 Jul 24.

PMID:
22831842
13.
14.
15.

Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.

Garnacho-Montero J, Amaya-Villar R, Ferrándiz-Millón C, Díaz-Martín A, López-Sánchez JM, Gutiérrez-Pizarraya A.

Expert Rev Anti Infect Ther. 2015 Jun;13(6):769-77. doi: 10.1586/14787210.2015.1032254. Epub 2015 Apr 12. Review.

PMID:
25865094
16.

Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.

Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC.

Diagn Microbiol Infect Dis. 2011 Jul;70(3):380-6. doi: 10.1016/j.diagmicrobio.2011.03.003. Epub 2011 May 10.

PMID:
21558048
17.

In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.

Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK, Park DW, Lee HJ, Lee MS, Ko KS.

J Med Microbiol. 2012 Mar;61(Pt 3):353-60. doi: 10.1099/jmm.0.036939-0. Epub 2011 Oct 20.

PMID:
22016557
19.

Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.

Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, Espejo-Gutiérrez de Tena E, Artero-González ML, Corcia-Palomo Y, Bautista-Paloma J.

Chemotherapy. 2013;59(3):225-31. doi: 10.1159/000356004. Epub 2013 Dec 13.

PMID:
24356297
20.

In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.

Ni W, Cui J, Liang B, Cai Y, Bai N, Cai X, Wang R.

J Antibiot (Tokyo). 2013 Dec;66(12):705-8. doi: 10.1038/ja.2013.84. Epub 2013 Aug 28.

PMID:
23981963

Supplemental Content

Support Center